___

• 1. Mangia A, Foster GR, Berg CP, et al; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin ther-apy in chronic hepatitis C: The real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43. 2. Furusyo N, Ogawa E, Nakamuta M, et al; Kyushu University Liver Disease Study (KULDS) Group. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepa-titis C. J Hepatol 2013;59:205-12.
• 3. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
• 4. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic re-view, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.
• 5. Alberti A, Piovesan S. Increased incidence of liver cancer after suc-cessful DAA treatment of chronic hepatitis C: Fact or fiction? Liver Int 2017;37:802-8